PRISM BioLab Co

PRISM BioLab Co Shares Outstanding

The The number of shares of PRISM BioLab Co (206A.T) as of Nov 7, 2026 is 36.93 M. In the previous year, The number of shares was 36.93 M — a change of 0.00% (lower).

Shares Outstanding

36.93 M

YoY

0.00%

Last updated:

In 2025, PRISM BioLab Co had 36.93 M outstanding stocks, a 0.00% change from the 36.93 M stocks in the previous year.

The PRISM BioLab Co Shares Outstanding history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Shares Outstanding
Date
Shares Outstanding
Jan 1, 2022
36.93 M JPY
Jan 1, 2023
36.93 M JPY
Jan 1, 2024
36.93 M JPY
Jan 1, 2025
36.93 M JPY
Jan 1, 2026 (e)
36.89 JPY
The PRISM BioLab Co Shares Outstanding history
YEARShares OutstandingYoY
est36.89-100.00%
36.93 M0.00%
36.93 M0.00%
36.93 M0.00%
36.93 M—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

PRISM BioLab Co Number of shares

PRISM BioLab Co shares outstanding

The number of shares of PRISM BioLab Co was 36.89 M in 2025. This indicates how many shares PRISM BioLab Co is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2022
36.96 M Stocks
Jan 1, 2023
36.96 M Stocks
Jan 1, 2024
36.10 M Stocks
Jan 1, 2025
36.89 M Stocks
Jan 1, 2026 (e)
36.89 M Stocks

PRISM BioLab Co Stock analysis

What does PRISM BioLab Co do? PRISM BioLab Co Ltd generates revenue through two distinct business models in the pharmaceuticals sector. The in-house development business focuses on selecting drug discovery targets and creating programs internally using their PepMetics technology platform. The joint development business collaborates with pharmaceutical companies to develop drug discovery programs leveraging their proprietary PepMetics technology. Both models utilize the company's owned drug discovery platform to create new pharmaceutical products. The company's primary clients are pharmaceutical companies seeking to develop new drugs through partnerships with PRISM BioLab's technology. PRISM BioLab's business model centers on its PepMetics technology, which serves as the foundation for both its in-house development and joint development segments. The company builds new drug discovery platforms and develops new drugs through these segments, targeting pharmaceutical companies as their main customers. The firm's research and development activities are conducted using their owned technology, which differentiates their approach in the drug discovery market. The company's revenue streams are derived from pharmaceutical companies that partner with PRISM BioLab for drug discovery programs. By utilizing their PepMetics technology platform, the company creates targeted drug discovery solutions that are developed either internally or in collaboration with pharmaceutical partners. This approach allows PRISM BioLab to generate income through both direct development efforts and collaborative projects with industry clients. PRISM BioLab Co is one of the most popular companies on Eulerpool.

Shares Outstanding Details

Evaluating PRISM BioLab Co's Shares Outstanding

PRISM BioLab Co's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in PRISM BioLab Co’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding PRISM BioLab Co’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in PRISM BioLab Co’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about PRISM BioLab Co stock

The number of shares of PRISM BioLab Co is 36.93 M in 2025.

The number of shares of PRISM BioLab Co changed from 36.93 M to 36.93 M, representing a 0.00% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The number of shares PRISM BioLab Co since 2006 – with annual values, charts, and detailed analysis.

The number of shares indicates the total number of a company's shares. This includes not only the shares available on the market, but also the shares held by shareholders and the shares retained by the company.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Other — PRISM BioLab Co

All Key Metrics — PRISM BioLab Co